Cargando…

If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism

BACKGROUND: Parkinson’s disease (PD) is a synucleinopathy, which presents dysautonomia, as its common non-motor symptom. Some research suggests the existing interplay between the autonomic nervous system dysfunction and glucose metabolism dysregulation in PD. OBJECTIVE: To determine the prevalence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chmiela, Tomasz, Węgrzynek, Julia, Kasprzyk, Amadeusz, Waksmundzki, Damian, Wilczek, Dawid, Gorzkowska, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109887/
https://www.ncbi.nlm.nih.gov/pubmed/35586204
http://dx.doi.org/10.2147/DMSO.S359856
_version_ 1784708976899784704
author Chmiela, Tomasz
Węgrzynek, Julia
Kasprzyk, Amadeusz
Waksmundzki, Damian
Wilczek, Dawid
Gorzkowska, Agnieszka
author_facet Chmiela, Tomasz
Węgrzynek, Julia
Kasprzyk, Amadeusz
Waksmundzki, Damian
Wilczek, Dawid
Gorzkowska, Agnieszka
author_sort Chmiela, Tomasz
collection PubMed
description BACKGROUND: Parkinson’s disease (PD) is a synucleinopathy, which presents dysautonomia, as its common non-motor symptom. Some research suggests the existing interplay between the autonomic nervous system dysfunction and glucose metabolism dysregulation in PD. OBJECTIVE: To determine the prevalence of metabolic disorders with particular emphasis on glucose metabolism in patients with PD and atypical parkinsonism (AP). PATIENTS AND METHODS: A retrospective study was performed by analyzing 461 clinical data of consecutive patients diagnosed with PD, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) hospitalized from 2019 to 2021 in the authors’ institution. The study group included 350 patients (303 PD, 14 MSA, 33 PSP), aged 65.8 ± 9.7 years (42% were female). Laboratory results (fasting glycemia, lipid parameters, TSH, homocysteine and vitamin D3 levels) were collected. The patient’s clinical condition was assessed in III part of Unified Parkinson’s Disease Rating Scale (UPDRS p. III), Hoehn–Yahr scale, Mini Mental State Examination (MMSE) and Beck Depression Inventory (BDI). RESULTS: Impaired fasting glycemia (IGF) was more prevalent in PD than in the PSP (43.43% vs 18.18%; p = 0.043). Similarly, PD presented a higher level of fasting glycemia (102.4 ± 16.7 mg/dl vs 92.2 ± 16.1mg/dl; p = 0.042). According to lipid parameters, patients with PD showed lower LDL cholesterol (92.3 ± 44.3mg/dl vs 119 ± 61.0mg/dl; p = 0.016) and lower BMI compared to patients with PSP (26.1 ± 4.0kg/m(2) vs 29.3 ± 4.4 kg/m(2); p = 0.024), but there were no statistically significant differences in triglycerides (TG) and HDL cholesterol levels. Males with PD presented greater frequency of IFG (35.05% vs 50.6%; p = 0.042), higher fasting glycemia (99.1 ± 14.3mg/dl vs 103.7 ± 14.7mg/dl; p = 0.006), lower total cholesterol, HDL cholesterol, and BMI compared to women with PD. CONCLUSION: Our investigation supports an association between synucleinopathies and glucose metabolism dysregulation.
format Online
Article
Text
id pubmed-9109887
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91098872022-05-17 If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism Chmiela, Tomasz Węgrzynek, Julia Kasprzyk, Amadeusz Waksmundzki, Damian Wilczek, Dawid Gorzkowska, Agnieszka Diabetes Metab Syndr Obes Original Research BACKGROUND: Parkinson’s disease (PD) is a synucleinopathy, which presents dysautonomia, as its common non-motor symptom. Some research suggests the existing interplay between the autonomic nervous system dysfunction and glucose metabolism dysregulation in PD. OBJECTIVE: To determine the prevalence of metabolic disorders with particular emphasis on glucose metabolism in patients with PD and atypical parkinsonism (AP). PATIENTS AND METHODS: A retrospective study was performed by analyzing 461 clinical data of consecutive patients diagnosed with PD, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) hospitalized from 2019 to 2021 in the authors’ institution. The study group included 350 patients (303 PD, 14 MSA, 33 PSP), aged 65.8 ± 9.7 years (42% were female). Laboratory results (fasting glycemia, lipid parameters, TSH, homocysteine and vitamin D3 levels) were collected. The patient’s clinical condition was assessed in III part of Unified Parkinson’s Disease Rating Scale (UPDRS p. III), Hoehn–Yahr scale, Mini Mental State Examination (MMSE) and Beck Depression Inventory (BDI). RESULTS: Impaired fasting glycemia (IGF) was more prevalent in PD than in the PSP (43.43% vs 18.18%; p = 0.043). Similarly, PD presented a higher level of fasting glycemia (102.4 ± 16.7 mg/dl vs 92.2 ± 16.1mg/dl; p = 0.042). According to lipid parameters, patients with PD showed lower LDL cholesterol (92.3 ± 44.3mg/dl vs 119 ± 61.0mg/dl; p = 0.016) and lower BMI compared to patients with PSP (26.1 ± 4.0kg/m(2) vs 29.3 ± 4.4 kg/m(2); p = 0.024), but there were no statistically significant differences in triglycerides (TG) and HDL cholesterol levels. Males with PD presented greater frequency of IFG (35.05% vs 50.6%; p = 0.042), higher fasting glycemia (99.1 ± 14.3mg/dl vs 103.7 ± 14.7mg/dl; p = 0.006), lower total cholesterol, HDL cholesterol, and BMI compared to women with PD. CONCLUSION: Our investigation supports an association between synucleinopathies and glucose metabolism dysregulation. Dove 2022-05-09 /pmc/articles/PMC9109887/ /pubmed/35586204 http://dx.doi.org/10.2147/DMSO.S359856 Text en © 2022 Chmiela et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chmiela, Tomasz
Węgrzynek, Julia
Kasprzyk, Amadeusz
Waksmundzki, Damian
Wilczek, Dawid
Gorzkowska, Agnieszka
If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism
title If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism
title_full If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism
title_fullStr If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism
title_full_unstemmed If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism
title_short If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism
title_sort if not insulin resistance so what? – comparison of fasting glycemia in idiopathic parkinson’s disease and atypical parkinsonism
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109887/
https://www.ncbi.nlm.nih.gov/pubmed/35586204
http://dx.doi.org/10.2147/DMSO.S359856
work_keys_str_mv AT chmielatomasz ifnotinsulinresistancesowhatcomparisonoffastingglycemiainidiopathicparkinsonsdiseaseandatypicalparkinsonism
AT wegrzynekjulia ifnotinsulinresistancesowhatcomparisonoffastingglycemiainidiopathicparkinsonsdiseaseandatypicalparkinsonism
AT kasprzykamadeusz ifnotinsulinresistancesowhatcomparisonoffastingglycemiainidiopathicparkinsonsdiseaseandatypicalparkinsonism
AT waksmundzkidamian ifnotinsulinresistancesowhatcomparisonoffastingglycemiainidiopathicparkinsonsdiseaseandatypicalparkinsonism
AT wilczekdawid ifnotinsulinresistancesowhatcomparisonoffastingglycemiainidiopathicparkinsonsdiseaseandatypicalparkinsonism
AT gorzkowskaagnieszka ifnotinsulinresistancesowhatcomparisonoffastingglycemiainidiopathicparkinsonsdiseaseandatypicalparkinsonism